Latest Marketable Securities News

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Novo Resources narrowed its Q1 2026 net loss to CAD 685K, boosted cash to CAD 10.6M following a $5.9M placement, and outlined aggressive gold and antimony drilling campaigns in Australia.

Freehill Mining has secured and reviewed the Mineral Resource Estimate block model for its Blanco y Negro copper-gold project in Chile, enabling accelerated underground mine planning and highlighting growth potential amid a strengthening copper market.

EBR Systems accelerated its U.S. commercial rollout of the WiSE CRT System in Q1 2026 with implant volumes more than doubling and revenue hitting US$2.4 million. The company also secured a key regulatory milestone in Australia with TGA Priority Review, yet losses deepened and cash burn intensified, raising fresh questions about its funding runway.

Block, Inc. reported a robust Q1 2026 with AI-powered productivity gains, strong Cash App and Square growth, and a $5 billion share buyback boost. Despite a GAAP net loss due to restructuring and legal costs, the fintech giant raised its full-year outlook, signaling confidence in its AI-led transformation.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Region Group has extended its on-market securities buy-back program by 12 months, aiming to optimise its portfolio while maintaining capital for growth opportunities.

Novo Resources Corp. reported a net loss of CAD 22.4 million for 2025, slightly improving from the previous year, while securing a $5.9 million capital raise to support ongoing exploration and operations.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

Dexus Convenience Retail REIT has extended its on-market securities buy-back program for another year, aiming to repurchase up to 2.5% of its securities to enhance shareholder value amid current trading conditions.

Dexus Industria REIT has announced an on-market securities buy-back targeting 2.5% of its issued securities, aiming to enhance returns for investors. The buy-back is set to commence from 24 March 2026 following a mandatory waiting period.